Pituitary hormones have long been thought solely to regulate single targets. Challenging this paradigm, we discovered that both anterior and posterior pituitary hormones, including FSH, had other functions in physiology. We have shown that FSH regulates skeletal integrity, and, more recently, find that the inhibition of FSH reduces body fat and induces thermogenic adipose tissue. A polyclonal antibody raised against a short, receptor-binding epitope of FSHβ was found not only to rescue bone loss post-ovariectomy, but also to display marked anti-obesity and pro-beiging actions. Questioning whether a single agent could be used to treat two medical conditions of public health importance -osteoporosis and obesity -we developed two further monoclonal antibodies, Hf2 and Mf4, against computationally defined receptor-binding epitopes of FSHβ. Hf2 has already been shown to reduce body weight, fat mass and cause beiging in mice on a high-fat diet. Here, we show that Hf2, which binds mouse Fsh in immunoprecipitation assays, also increases cortical thickness and trabecular bone volume, and microstructural parameters, in sham-operated and ovariectomized mice, noted on micro-computed tomography.
SIGNIFICANCE STATEMENT
We have addressed the question whether osteoporosis and obesity, which often occur concurrently in postmenopausal women, can be targeted by a single agent. We have shown previously that the reproductive hormone FSH, the levels of which rise after menopause, regulates both body fat and bone mass. We now show that blocking FSH action using two purposefully designed epitope-specific antibodies protects against bone loss in mice. This positions both FSH antibodies as lead molecules for clinical development towards future use in people.
INTRODUCTION
FSH levels rise when procreation ceases as a consequence of ovarian failure. This period in a woman's life is associated with marked changes in body physiology (1) . Bone is lost at the most rapid rate beginning two to three years prior to the cessation of menstruation (2, 3) .
During this time, estrogen levels are relatively unperturbed, whereas FSH levels are rising (4) , and there is a tight correlation between plasma FSH levels and bone loss, independently of estrogen levels (2) . This reduced bone mass is also accompanied by increases in visceral adiposity, a disruption of energy metabolism, and decreased physical activity (5, 6 ). These aberrations have been shown, in clinical studies, to be reversed by pharmacologic doses of estrogen (7) .
Our studies have shown that FSH directly affects both bone and fat (8, 9) . We and others find that these actions of FSH are mediated through a low-abundance G protein-coupled FSH receptor (FSHR) identified on osteoclasts (9) , mesenchymal stem cells (10) , and adipocytes (8, 11, 12) , as well as in bone tissue in vivo (13) . Unlike the ovary where FSHR-G αs coupling is well documented, the receptor found in bone and fat tissue couples to a G αi protein (9) , the activation of which reduces cAMP levels. In bone this translates into enhanced osteoclastogenesis and reduced osteoblastogenesis via reductions in MAP kinase and NFκ-B signaling (9) , whereas in fat tissue, the FSHR is coupled to reduced UCP1 expression (8, 12) .
The crystal structure of the human FSHR-FSH complex indicates that the FSHβ subunit binds to specific amino acids in the FSHR binding groove (14) . By modeling the Fshr-Fsh interaction in mouse, we developed a polyclonal antibody to a 13-amino acid sequence in the binding domain of Fshβ (12, 15, 16) .
Injection of this polyclonal antibody prevented ovariectomy-induced bone loss through a dual action, notably through a reduction in bone resorption and stimulation of new bone synthesis (15) . In separate studies, the antibody triggered a dramatic reduction of visceral and subcutaneous fat in not only in ovariectomized mice, but also in both male and female wild type mice that were fed on a high-fat diet or on normal chow but allowed to eat ad libitum (12) . This phenotype was associated with profound beiging of white adipose tissue (WAT), brown adipose tissue (BAT) activation, increased cellular mitochondrial density, and a thermogenic response (12) . These findings, together, have presented FSH as a therapeutic target for postmenopausal bone loss and for obesity in contexts beyond and including the menopause.
Here, we present two monoclonal antibodies directed against receptor-binding sequences of human or mouse FSHβ, but which are not species-specific. Hf2 was raised against the human FSHβ epitope and Mf4 against the mouse Fshβ epitope. Computational modeling of the mouse Fshr-Fsh complex revealed that the epitope mapped to specific amino acids in the Fsh-binding pocket of the Fshr. Both antibodies showed significant osteoprotection in ovariectomized and/or sham-operated mice.
Histomorphometry on Mf4-treated ovariectomized mice further showed reduced osteoclastic bone resorption, and increased bone formation rates and osteoblast numbers. Furthermore, we find that fluorescently labeled recombinant human FSH, namely, FSH-CH1055 (FSH-CH), binds to bone tissue in vivo, and that injecting unconjugated FSH reverses this binding. Our findings thus establish FSH as a hormonal regulator of bone (and fat), and underscore the potential utility of humanized monoclonal antibodies for the therapy of both osteoporosis and obesity.
RESULTS
We developed two anti-FSHβ monoclonal antibodies using synthetic peptides based on the Fshr-binding sequence (LVYKDPARPNTQK) of mouse Fshβ that was used to generate our polyclonal antibody. The corresponding sequence for human Fshβ is LVYKDPARPKIQK, which represents a two amino acid difference. We fine mapped the atomic interactions between these sequences and the respective parent FSHRs. The crystal structure of human FSH in complex with the entire ectodomain of the human FSHR (PDB id 4AY9) was used as the template for comparative modeling (Fig. 1A) . High sequence identity between mouse Fshr (UniProt id Q9QWV8) and human FSHR (88%) permitted for an accurate homology model to be constructed (Fig. 1B) . In the human complex, residue R44 of β-chain forms an ion pair with residue E197 of the FSHR (Fig. 1A) . Residue K49 forms another stable ion pair with residue E332 of the receptor. The sulphate group of the modified residue sTyr335 acts as hydrogen bond acceptor of the backbone amines of residues Y39 and V38. Furthermore, residue Y39
forms a hydrogen bond with residue H289 of the FSHR, and residue K242 is a hydrogen bond donor to the backbone of the residue A43. The modeled mouse Fshr-Fshβ complex largely has a similar binding mode to the human complex, with an additional interaction through which residue D41 makes a hydrogen bond with residue K242 of the receptor (Fig. 1B) . Of note is that the N46 and T47 residues in mouse Fshβ and corresponding K46 and I47 residues in human FSHβ were found not to interact with the respective receptors (Figs. 1A and 1B).
To further confirm the expression of Fshr in bone, we injected FSH-CH, a recombinant human FSH protein conjugated to the near-infrared II (NIR-II) fluorophore CH1055, into the tail vein of Balb/c mice. NIR-II fluorescence was detected in the ovaries and the skeleton (Fig. 1C ).
The binding of FSH-CH to these tissues was specific, as the NIR-II signal was attenuated in the presence of a 30-fold excess of unconjugated FSH (Fig. 1C ).
The structure of both human and mouse (modeled) FSHR resembles a right hand palm, with the main body as the palm and the protruding hairpin loop as the thumb (Figs. 1A and 1B).
FSHβ binds in the groove generated between the palm and the thumb. Thus, we expect that the binding of the FSHR-binding sequence to an IgG (antibody) would block the entry of FSHβ into the receptor pocket. With experimental evidence that this is indeed the case with our mouse polyclonal Fshβ antibody (12), we generated two therapeutically-directed monoclonal antibodies against the two aforementioned FSHR-binding sequences. Namely, for antibody Mf4 and Hf2, we used appropriately elongated synthetic peptides, CLVYKDPARPNTQKV and YCYTRDLVYKDPARPKIQKTCT, respectively, for immunization (GenScript).
As a prelude to the testing of Hf2 in mice, we first determined whether it recognized mouse Fshβ. Recombinant mouse Fsh was used to spike HEK293 cell lysate, which was passed through resin with immobilized polyclonal Fsh antibody that was raised against the corresponding mouse LVYKDPARPNTQK-containing Fsh motif. Immunoblotting with Hf2 revealed a ~50 kDa band in both elution and flow-through fractions that had passed through the immobilized polyclonal Fsh antibody, whereas unspiked HEK293 cell lysate did not yield an immunoreactive FSH band in any fraction ( Fig. 2A ). This established that mouse FSH captured specifically by a polyclonal antibody was detected by Hf2.
We have shown previously that the antibody Hf2, when administered to male mice on a high-fat diet, triggered a reduction in visceral and subcutaneous fat and caused profound beiging (12) . Here, we find that Hf2 causes an increase in tibial cortical thickness (Ct.Th) and reduction in marrow area in sham-operated mice fed on normal chow (Fig. 2B ). This was accompanied by a marked increase in trabecular bone mineral density (BMD), in both shamoperated and ovariectomized mice (Fig. 2C) . Statistically significant or marginal increases were also noted in fractional bone volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and connectivity density (Conn.D), with reciprocal decrements in trabecular spacing (Tb.Sp) (Fig. 2C) . These results confirm our premise that Hf2, raised against the human FSHβ epitope, could potentially be utilized for increasing bone mass in addition to its documented effect in reducing body fat (12) . added Fsh in a concentration-dependent manner, which was indeed the case (Fig. 3A) .
However, to establish FSH specificity, we spiked the medium with 30 ng/mL Fsh, and found that the stimulation by Fsh of osteoclastogenesis (seen at zero-dose of Mf4) was progressively attenuated with increasing Mf4 concentrations. This result was identical to that with the polyclonal antibody (Fig. 3B) . Similarly, Hf2 inhibited osteoclastogenesis in a dose-dependent manner ( (Fig. 3D) . Histomorphometry revealed significant reductions in osteoclast number (N.Oc) and resorbed surface (Oc.S) in Mf4-treated ovariectomized mice, measured both at the spine and tibial head, indicating a potent effect of Mf4 in reducing osteoclastic bone resorption (Fig.   4A ). Specifically, in the tibial head, there was a significant increase in Oc.S and N.Oc expectedly following ovariectomy, and this was reduced to baseline in Mf4-treated mice.
Consistent with the histomorphometry data, expression of osteoclast-specific genes, namely acid phosphatase 5, tartrate resistant (Acp5, also known as Trap) and matrix metalloproteinase-9 (Mmp9), were reduced in osteoclasts derived from Mf4-treated ovariectomized mice compared to IgG-treated control (Fig. 4B) . We next studied the effect of Mf4 on bone formation by dynamic histomorphometry following dual calcein and xylelol orange labeling. Little change was noted with Mf4 treatment in the sham-operated group. However, in ovariectomized mice, Mf4 triggered significant increases in mineralized surface (MS) and bone formation rate (BFR), as well as in osteoblast numbers (Ob.N) (Figs. 4C and 4D) . Importantly, Mf4 did not alter estrogen levels in wild type mice (Fig. 4D) . Together, the effects of Mf4 in increasing bone mass, inhibiting bone resorption, and stimulating new bone formation were consistent with our earlier results with the polyclonal Fsh antibody raised to the same epitope (15) .
DISCUSSION
Several levels of association have emerged between the two global epidemics osteoporosis and obesity, which affect 100 and 600 million people, respectively, worldwide.
First, in contrast to prior assumptions that fat mass begets bone mass, it is now clear from epidemiological studies that obesity tracks with osteoporosis (18) (19) (20) . Notably, there is a negative correlation between bone mass and fat mass in both rodents and in people [e.g. (18, 20) ]. Second, during the menopausal transition, the rapid bone loss that leads to high fracture rates accompanies the onset of visceral fat accumulation (2, 3, 6); the latter, if left unchecked, predisposes to metabolic syndrome, cardiovascular disease, and cancer. The late perimenopause, in particular, is associated with rising FSH levels in the face of normal estrogen (4), raising the question whether estrogen deficiency is the sole cause of these physiologic aberrations. Third, bone marrow adiposity, often seen as a function of aging and sex steroid deficiency, is linked with osteoporosis (21, 22) . These associations lay the basis not only for overlapping molecular mechanisms that underpin both osteoporosis and obesity, but also for a new therapeutic approach to treat these two diseases simultaneously. We surmise that FSH, a fertility hormone, is one such molecule that regulates both osteoblast progenitors and adipocytes. This fundamental premise also makes biological sense as osteoblasts, cells that build new bone, and adipocytes derive from the same mesenchymal progenitor (23) .
With a therapeutic goal in mind, rather than generating antibodies to the intact FSHβ molecule, we chose to target a short epitope that, upon computational modeling, was found to interact with specified amino acids in the ligand-binding pocket of the Fshr. We made the assumption that the binding of an IgG to that site would block entry of active FSHβ into this restricted pocket, and hence, block FSH action. Experimentally, our polyclonal and monoclonal antibodies both blocked the stimulation of osteoclastogenesis induced by specifically FSH. This finding was consistent with previous results in which the polyclonal antibody inhibited FSHinduced Ucp1 activation in dedifferentiated brown adipocytes (Thermo cells) (12) .
Our proof-of-principle in vivo studies show that the inhibition of FSH action, either through genetic ablation of the Fshr or via pharmacological blockade using the epitope-specific FSH antibodies, results in significant osteoprotection in ovariectomized mice, and triggers the loss of body fat in multiple mouse models of obesity, including mice on a high-fat diet, mice allowed to eat ad libitum, and in ovariectomized mice (12, 15) . Of note is that the FSH antibodies, at the dosages used, do not affect serum estrogen levels (12, 15) , but this does not rule out equally relevant effects of estrogen on both bone mass and body fat (7, (24) (25) (26) .
In addition to its action on bone and fat cells, we found previously that FSH directly upregulates the production of the inflammatory cytokine TNFα (27) . Mice genetically deficient in FSHβ thus showed reduced TNFα production from bone marrow macrophages (27) .
Furthermore, post-menopausal women, who lose bone and gain fat and have high circulating FSH, also display elevated TNFα levels (28) . Together, these findings suggest that part of the effects of FSH on bone may be TNFα-mediated. It is also possible that FSH promotes inflammation in visceral fat through TNFα production. There is mounting evidence that systemic inflammation, particularly in perivascular fat, contributes to obesity-associated cardiovascular risk (29, 30) . A question arises, therefore, whether, in addition to reducing bone loss, FSH blockade might also reduce TNFα-mediated inflammation, and whether this can translate into reduced vasculopathy and cardiovascular disease.
In summary, we confirm through genetic and pharmacological strategies that blocking FSH action on its receptor promotes health by stimulating new bone formation, reducing bone removal, and inhibiting fat accumulation. One would ask whether FSH, while being critical for procreation, becomes a catabolic hormone after procreation ceases in women. And, more importantly, whether the effects of FSH, together, could contribute to alterations in longevity?
Indeed, there is evidence that Prop1 df mice (Ames dwarfs) and Ghr -/-mice (Laron dwarfs) with low circulating FSH levels live longer depending on diet, gender and genetic background (31) (32) (33) . This increase in longevity is associated with the maintenance of youthful levels of cognitive and neuromuscular function, and a reduced rate of aging (33) . If the noted pro-aging actions are FSH-dependent, they could represent a new mechanism for the trade-off between fertility and longevity (33) . Could FSH thus also be a primary aging hormone?
METHODS
For comparative modeling, we used the crystal structure of the human FSH in complex with the entire ectodomain of the human FSHR as the template (PDB id 4AY9) (14) . Sequence of mouse Fshr was obtained from UniProt (id Q9QWV8) and homology construction was achieved using Modeller (34), with stereochemical parameters being checked using PROCHECK (35) and PROSA (36) . For molecular dynamics (MD), 5 ns of constant number, volume and energy (NVE) MD production was carried out using a 1 fs time step; periodic boundary conditions were used; and the accuracy of the particle mesh Ewald (PME) was increased by reducing the direct sum tolerance (DSUM_TOL) by an order of magnitude (0.000001). Strong restraints were applied over the backbone atoms of the four residues surrounding the missing loop: K294-S295 and S331-D332. was performed using a protocol described previously (12) . 
